Home
>
Company Dynamics
>
News
News
Injections are gradually becoming the protagonist of the market
2023/5/31
Viewed：
On June 1st,Pharmaceutical Network reported that the Qinghai Provincial Medical Insurance Bureau recently issued a notice on the submission of data related to centralized procurement of drugs by provincial organizations in 2020.It released a list of drugs for centralized procurement in Qinghai Province in 2020,including 49 varieties such as human serum albumin,Xuesaitong,Shenkang,and butylphthalide.As a result,another provincial-level procurement catalog has emerged,attracting industry attention.
The institutions participating in the volume procurement of drugs in Qinghai Province include public medical institutions and military medical institutions,and encourage designated social medical institutions under medical insurance to voluntarily participate in data submission and centralized drug procurement.The procurement quantity of grassroots medical institutions shall be uniformly summarized and reported by hospitals led by the county medical community.
The notice requires medical institutions to fill in the estimated procurement quantity from July 1,2020 to June 30,2021 based on actual clinical needs,and the data submission time is from May 26 to June 5.After the data submission phase ends,provincial centralized procurement in Qinghai Province may begin.
This time,the purchase catalogue of Qinghai Province in quantity included many interesting varieties and dosage forms,such as traditional Chinese patent medicines and simple preparations,biological agents,eye drops,inhalants,etc.
Previous blind spots in centralized procurement
According to Saberlan,up to now,provinces and cities such as Shandong,Shanxi,Hunan,Hebei,Jiangxi,Wuhan,Fujian,Sanming,Jinhua,Shandong Yantai,and Dezhou have carried out bulk procurement work on their respective determined centralized procurement varieties.
Some insiders said to Cybertron that for some time,whether it is national or provincial or municipal centralized procurement,it is mainly targeted at chemical drugs,and traditional Chinese patent medicines and simple preparations and biological drugs are rarely listed in the centralized procurement catalog.
As for the reason,from the perspective of national centralized purchase,the bottom line requirement is to pass consistency evaluation,while traditional Chinese patent medicines and simple preparations cannot be included in the procurement scope because there is no evaluation method at present;From the perspective of provincial and municipal levels,the key monitoring and rational drug use system is still being steadily implemented within the framework of performance evaluation in public hospitals.Many traditional Chinese medicine injections are listed as key monitoring varieties in some provinces and cities,and there are corresponding restrictions on the dosage in hospitals.However,if purchased in large quantities,it is necessary to encourage their use.It is not difficult to see that there may be contradictions among them.
With regard to the reevaluation of traditional Chinese patent medicines and simple preparations that needs to be transcended when it enters the national centralized procurement,Shi Lichen,founder of Beijing Dingchen Medical Management Consulting Center,further said to Cybertron that there is no precedent in the world for clinical reevaluation of traditional Chinese medicine after it is launched,and it will take a long time for relevant national departments to set standards,evaluate which key elements and indicators need to be explored.
Why is there less centralized procurement for biopharmaceuticals?Dong Lei,General Manager of Tiandong Pharmaceutical,told Cyberblue that on the one hand,it may be because many biopharmaceutical production capacity is relatively limited,and it is difficult to meet market supply by retaining only a small number of manufacturers;On the other hand,it may be because there are fewer production companies in the biopharmaceutical market and competition is not as strong.
Shi Lichen also pointed out that since biopharmaceuticals have only developed in recent years,the initial product quality level was relatively high,with most of them being new drugs,and the overall usage and oral dosage were also relatively small.
The scope of centralized procurement of injections may be expanded
According to Saberlan,in the centralized procurement catalog of Qinghai Province,there are 33 injection types,3 inhalation formulations,2 eye drops,and the rest are oral formulations for 49 varieties.Injections have become the main focus of this centralized procurement in Qinghai.
Coincidentally,in addition to Qinghai Province,Shanxi Province has also focused on centralized procurement of injections.On April 20th,Shanxi Province officially launched the first batch of drug group alliances for centralized and volume procurement.In Shanxi"s centralized procurement catalog,21 drugs are all injections,such as docetaxel,levofloxacin,enoxaparin,ambroxol,and levocarnitine.
In addition,on April 23rd,the Shandong Provincial Medical Insurance Bureau issued a notice on organizing the filling out of partial drug procurement plans,announcing the start of mass procurement in the province.Finally,Shandong Province selected 40 varieties,including aspirin,nifedipine,metoprolol,fluroxine,omeprazole,rabeprazole,compound glycyrrhizin,lansoprazole,and levamlodipine,of which 27 were injection and 13 were oral,accounting for more than two-thirds.
From the increasing efforts of multiple provinces in the centralized procurement of injections,it can be seen that although the first two rounds of national centralized procurement have been carried out so far,oral preparations are still the main focus.However,with the progress of consistency evaluation work and the increase of enterprises and varieties that have passed the evaluation,the proportion of injections in subsequent national centralized procurement may continue to increase.
The institutions participating in the volume procurement of drugs in Qinghai Province include public medical institutions and military medical institutions,and encourage designated social medical institutions under medical insurance to voluntarily participate in data submission and centralized drug procurement.The procurement quantity of grassroots medical institutions shall be uniformly summarized and reported by hospitals led by the county medical community.
The notice requires medical institutions to fill in the estimated procurement quantity from July 1,2020 to June 30,2021 based on actual clinical needs,and the data submission time is from May 26 to June 5.After the data submission phase ends,provincial centralized procurement in Qinghai Province may begin.
This time,the purchase catalogue of Qinghai Province in quantity included many interesting varieties and dosage forms,such as traditional Chinese patent medicines and simple preparations,biological agents,eye drops,inhalants,etc.
Previous blind spots in centralized procurement
According to Saberlan,up to now,provinces and cities such as Shandong,Shanxi,Hunan,Hebei,Jiangxi,Wuhan,Fujian,Sanming,Jinhua,Shandong Yantai,and Dezhou have carried out bulk procurement work on their respective determined centralized procurement varieties.
Some insiders said to Cybertron that for some time,whether it is national or provincial or municipal centralized procurement,it is mainly targeted at chemical drugs,and traditional Chinese patent medicines and simple preparations and biological drugs are rarely listed in the centralized procurement catalog.
As for the reason,from the perspective of national centralized purchase,the bottom line requirement is to pass consistency evaluation,while traditional Chinese patent medicines and simple preparations cannot be included in the procurement scope because there is no evaluation method at present;From the perspective of provincial and municipal levels,the key monitoring and rational drug use system is still being steadily implemented within the framework of performance evaluation in public hospitals.Many traditional Chinese medicine injections are listed as key monitoring varieties in some provinces and cities,and there are corresponding restrictions on the dosage in hospitals.However,if purchased in large quantities,it is necessary to encourage their use.It is not difficult to see that there may be contradictions among them.
With regard to the reevaluation of traditional Chinese patent medicines and simple preparations that needs to be transcended when it enters the national centralized procurement,Shi Lichen,founder of Beijing Dingchen Medical Management Consulting Center,further said to Cybertron that there is no precedent in the world for clinical reevaluation of traditional Chinese medicine after it is launched,and it will take a long time for relevant national departments to set standards,evaluate which key elements and indicators need to be explored.
Why is there less centralized procurement for biopharmaceuticals?Dong Lei,General Manager of Tiandong Pharmaceutical,told Cyberblue that on the one hand,it may be because many biopharmaceutical production capacity is relatively limited,and it is difficult to meet market supply by retaining only a small number of manufacturers;On the other hand,it may be because there are fewer production companies in the biopharmaceutical market and competition is not as strong.
Shi Lichen also pointed out that since biopharmaceuticals have only developed in recent years,the initial product quality level was relatively high,with most of them being new drugs,and the overall usage and oral dosage were also relatively small.
The scope of centralized procurement of injections may be expanded
According to Saberlan,in the centralized procurement catalog of Qinghai Province,there are 33 injection types,3 inhalation formulations,2 eye drops,and the rest are oral formulations for 49 varieties.Injections have become the main focus of this centralized procurement in Qinghai.
Coincidentally,in addition to Qinghai Province,Shanxi Province has also focused on centralized procurement of injections.On April 20th,Shanxi Province officially launched the first batch of drug group alliances for centralized and volume procurement.In Shanxi"s centralized procurement catalog,21 drugs are all injections,such as docetaxel,levofloxacin,enoxaparin,ambroxol,and levocarnitine.
In addition,on April 23rd,the Shandong Provincial Medical Insurance Bureau issued a notice on organizing the filling out of partial drug procurement plans,announcing the start of mass procurement in the province.Finally,Shandong Province selected 40 varieties,including aspirin,nifedipine,metoprolol,fluroxine,omeprazole,rabeprazole,compound glycyrrhizin,lansoprazole,and levamlodipine,of which 27 were injection and 13 were oral,accounting for more than two-thirds.
From the increasing efforts of multiple provinces in the centralized procurement of injections,it can be seen that although the first two rounds of national centralized procurement have been carried out so far,oral preparations are still the main focus.However,with the progress of consistency evaluation work and the increase of enterprises and varieties that have passed the evaluation,the proportion of injections in subsequent national centralized procurement may continue to increase.
More
Related products
